Invention Grant
US08455629B2 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
有权
人抗OPGL中和抗体作为选择性OPGL途径抑制剂
- Patent Title: Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
- Patent Title (中): 人抗OPGL中和抗体作为选择性OPGL途径抑制剂
-
Application No.: US13360454Application Date: 2012-01-27
-
Publication No.: US08455629B2Publication Date: 2013-06-04
- Inventor: William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- Applicant: William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- Applicant Address: US CA Thousand Oaks US NJ Princeton
- Assignee: Amgen Inc.,Medarex, Inc.
- Current Assignee: Amgen Inc.,Medarex, Inc.
- Current Assignee Address: US CA Thousand Oaks US NJ Princeton
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12P21/02 ; C12P21/08 ; C12N5/16
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Public/Granted literature
- US20120156725A1 Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors Public/Granted day:2012-06-21
Information query
